BioSymetrics brings clinical data analysis, target discovery, virtual screening, mechanism analysis, and experimental validation into partner programs.
Our offerings connect analysis and validation across discovery. Partners can draw on a focused capability or connect several across a workflow, adding our analytics and translational biology to their data, disease expertise, assets, and research teams.
We can support patient stratification, biomarker and target discovery, hit and mechanism interpretation, or in vivo validation. These capabilities give partners evidence and focused next steps for research and development decisions.
Our offerings link multimodal clinical data with target hypotheses, virtual screening, and experimental readouts across a discovery workflow.
Our Clinical Insights platform connects longitudinal clinical, genomic, imaging, and outcomes data to identify patient subgroups, biomarkers, and disease mechanisms. Our Phenograph™ maps human and model system phenotypes to genes, pathways, targets, and therapies.
Using human and model system phenotypes, our platform predicts the effects of disrupting thousands of genes in silico and ranks candidate targets and hypotheses for follow-up experiments.
Our automated zebrafish assays and computer vision quantify morphology, physiology, and behaviour. MOA Miner analyzes phenotype screening hits to rank possible targets, mechanisms of action, and pathways.
Bring us a disease question, patient dataset, discovery program, or phenotype screen, and we can explore which BioSymetrics offerings fit the work.
Partner with us